Medicare: GLP-1 Weight-Loss Drug Demonstration Begins July 2026
Starting in July 2026, some people with Medicare will be eligible for Medicare coverage of certain weight-loss medications through the new Medicare GLP‑1 Bridge Program.
Background
Under federal law, Medicare Part D plans cannot cover medications prescribed for weight loss, among several other “excluded” categories of drugs and indications. Medications that are FDA-approved for both weight loss and other indications may only be covered by Part D plans for non-weight loss indications.
GLP-1 drugs, which include medications used to treat type 2 diabetes, obesity, cardiovascular disease, and other conditions, have greatly increased in popularity in recent years due to their demonstrated effectiveness. But the federal exclusion limits Medicare coverage of these drugs.
Changing the law to permit or require Medicare Part D plans to cover medications for weight loss would require Congress to act. But the Centers for Medicare & Medicaid Services (CMS) has the authority to test coverage changes through Center for Medicare and Medicaid Innovation (CMMI) models and other statutory demonstration authorities.
https://www.medicarerights.org/medicare-watch/2026/06/04/glp-1-weight-loss-drug-demonstration-begins-july-2026